BB Biotech N
BION
CHF
STOCK MARKET:
SWX
Closed
 
...
Large gap with delayed quotes
Last quote
11/20/2026 - 17:30:23
Bid
11/20/2026 - 17:40:00
Bid
Volume
Ask
11/20/2026 - 17:40:00
Ask
Volume
52.60
0.00 ( 0.00% )
52.20
279
0.00
250
More information
Analysis by TheScreener
20.11.2026
Evaluation Positive  
Quality Very strong  
Risk Low  
Analysis date: 20.11.2026
Global Evaluation
  Positive
The stock is classified in the positive zone since 20.10.2026.
Quality
  Very strong
Four stars since 10.11.2026.
Earnings Rev Trend
  Positive
 
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 20.10.2026 at a price of 50.20.
Evaluation
  Undervalued
 
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
  Neutral
 
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 10.11.2026.
4wk Rel Perf
  6.82%
 
The four-week dividend-adjusted overperformance versus STOXX600 is 6.82%.
Risk
  Low
The stock has been on the low-sensitivity level since 24.02.2026.
Bear Market Factor
  Low
On average, the stock has a tendency to minimize the drops in the index by -0.27%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 1.88%.
Mkt Cap in $bn
  3.42
With a market capitalization between $2 & $8bn, BB BIOTECH AG is considered a mid-cap stock.
G/PE Ratio
  2.21
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
  11.66
The estimated PE is for the year 2027.
LT Growth
  20.78%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
  2
Over the last seven weeks, an average of 2 analysts provided earnings per share estimates.
Dividend Yield
  4.94%
The twelve month estimated dividend yield represents 57.64% of earnings forecasts.
Beta
  82
For 1% of index variation, the stock varies on average by 0.82%.
Correlation
  0.43
42.55% of stock movements are explained by index variations.
Value at Risk
  4.32
The value at risk is estimated at CHF 4.32. The risk is therefore 8.22%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  22.07.2014